PMID- 37224751
OWN - NLM
STAT- MEDLINE
DCOM- 20230622
LR  - 20230622
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 164
DP  - 2023 Aug
TI  - Therapeutic effects of methimazole on 3,4-methylenedioxymethamphetamine-induced 
      hyperthermia and serotonergic neurotoxicity.
PG  - 114880
LID - S0753-3322(23)00670-4 [pii]
LID - 10.1016/j.biopha.2023.114880 [doi]
AB  - 3,4-methylenedioxymethamphetamine (MDMA) is a popular recreational drug, however 
      over 200 studies demonstrate that acute (e.g. hyperthermia, rhabdomyolysis) and 
      chronic (e.g. neurotoxicity) toxicity effects of MDMA were observed in different 
      animals. Methimazole (MMI), an inhibitor of thyroid hormone synthesis, was found 
      to significantly reduce the HSP72 expression of heat stress induced in 
      fibroblasts. Hence, we attempted to understand the effects of MMI on MDMA induced 
      changes in vivo. Male SD rats were randomly divided into four groups as 
      follows:(a) water-saline (b) water-MDMA (c) MMI-saline and (d) MMI-MDMA group. In 
      the temperature analysis test, MMI was found to alleviate MDMA-induced 
      hyperthermia and increase the heat loss index (HLI), revealing its peripheral 
      vasodilation effect. PET experiment suggested that MDMA induced elevated glucose 
      uptake by skeletal muscles, which was resolved by MMI pretreatment. IHC staining 
      (serotonin transporter, SERT) showed the evidence of neurotoxicity caused by MDMA 
      (serotonin fiber loss), which was alleviated by MMI. Furthermore, the animal 
      behaviour test (forced swimming test, FST) showed higher swimming time but lower 
      immobility time in MMI-MDMA and MMI-saline groups. Taken together, treatment of 
      MMI shows benefits such as lowered body temperature, alleviation of neurotoxicity 
      and excited behaviour. However, further investigations should be conducted in the 
      future to provide in-depth evidence for its clinical use.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Li, I-Hsun
AU  - Li IH
AD  - Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan; 
      School of Pharmacy, National Defense Medical Center, Taipei, Taiwan; Department 
      of Pharmacology, National Defense Medical Center, Taipei, Taiwan.
FAU - Liu, Tsung-Ta
AU  - Liu TT
AD  - School of Pharmacy, National Defense Medical Center, Taipei, Taiwan; Department 
      of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan.
FAU - Chen, Ying-Chen
AU  - Chen YC
AD  - Department of Pharmacy, Fu Jen Catholic University Hospital, New Taipei City, 
      Taiwan.
FAU - Hsiao, Sheng-Huang
AU  - Hsiao SH
AD  - Department of Neurosurgery, Taipei City Hospital, Taipei, Taiwan.
FAU - Hung, Hao-Yuan
AU  - Hung HY
AD  - Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan; 
      Department of Pharmacology, National Defense Medical Center, Taipei, Taiwan.
FAU - Fann, Li-Yun
AU  - Fann LY
AD  - Department of Nursing, Taipei City Hospital, Taipei, Taiwan.
FAU - Shih, Jui-Hu
AU  - Shih JH
AD  - Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan; 
      School of Pharmacy, National Defense Medical Center, Taipei, Taiwan. Electronic 
      address: jtlovehl@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20230522
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - 554Z48XN5E (Methimazole)
SB  - IM
MH  - Rats
MH  - Male
MH  - Animals
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/toxicity
MH  - Methimazole/toxicity
MH  - Rats, Sprague-Dawley
MH  - Body Temperature
MH  - *Neurotoxicity Syndromes/drug therapy/etiology
MH  - *Hyperthermia, Induced/adverse effects
OTO - NOTNLM
OT  - Forced swimming test
OT  - Hyperthermia
OT  - MDMA
OT  - Methimazole
OT  - PET
OT  - Serotonergic neurotoxicity
COIS- Declaration of Competing Interest The authors declare that they have no conflict 
      of interest.
EDAT- 2023/05/25 01:07
MHDA- 2023/06/22 06:42
CRDT- 2023/05/24 18:08
PHST- 2023/03/15 00:00 [received]
PHST- 2023/05/05 00:00 [revised]
PHST- 2023/05/12 00:00 [accepted]
PHST- 2023/06/22 06:42 [medline]
PHST- 2023/05/25 01:07 [pubmed]
PHST- 2023/05/24 18:08 [entrez]
AID - S0753-3322(23)00670-4 [pii]
AID - 10.1016/j.biopha.2023.114880 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2023 Aug;164:114880. doi: 10.1016/j.biopha.2023.114880. Epub 
      2023 May 22.